CVE-2001-1389

Description

Multiple vulnerabilities in xinetd 2.3.0 and earlier, and additional variants until 2.3.3, may allow remote attackers to cause a denial of service or execute arbitrary code, primarily via buffer overflows or improper NULL termination.

7.5

CVSS

Severity: High

CVSS 2.0 •

EPSS 2.44% Top 20%

Vendor Advisory linux-mandrake.com Vendor Advisory immunix.org Vendor Advisory redhat.com

Affected: n/a n/a

References

Link	Tags
http://www.linux-mandrake.com/en/security/2001/MDKSA-2001-076.php3	vendor advisory
http://download.immunix.org/ImmunixOS/7.0/updates/IMNX-2001-70-033-01	vendor advisory
http://marc.info/?l=bugtraq&m=99913751525583&w=2	mailing list
http://rhn.redhat.com/errata/RHSA-2001-109.html	patch vendor advisory
http://www.securityfocus.com/bid/3257	vdb entry

Frequently Asked Questions

What is the severity of CVE-2001-1389?: CVE-2001-1389 has been scored as a high severity vulnerability.
How to fix CVE-2001-1389?: To fix CVE-2001-1389, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2001-1389 being actively exploited in the wild?: It is possible that CVE-2001-1389 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~2% probability that this vulnerability will be exploited by malicious actors in the next 30 days.

This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.